Table 3.
Outcomes of studies investigating the role of mTOR inhibitors
| Study | Intervention | Primary outcome | Secondary outcomes | Method of assessment | Outcome | |
|---|---|---|---|---|---|---|
| 1 year | 18 months | |||||
| Chrispijn M. et al22 | Everolimus | Liver volume | QoL | CT volumetry | Volume reduced by 3.5% and 3.8% in the control group and intervention groups.No significant difference between the two groups (p=0.73). | |
| Qian Q. et al23 | Sirolimus | Liver volume | Kidney volume | CT volumetry | Mean reduction of 11.3+/-0.03 % (p=0.048) in liver volume in sirolimus group | |